0158
![Text Box: BIFIDOBIOGEN WITH QINGGANLIDAN ORAL LIQUID TREATMENT HYPER-BILIRUBINEMIA OF NEONATAL
Zhang He, Han Ziming, Sheng Xinde, et al.
Department of Pediatrics, First Teaching Hospital of Xinxiang Medicial Collage, Xingxiang 453100, Henan, China
Objective: To observe the effects of bifidobiogen and qingganlidan oral liquid treat the neonatal hyperbilirubinemia.
Methods: Bifidobiogen and qingganlidan oral liquid were administered together with conventional treatment.
Result: The level of serum bilirubin decreased by average of (54.38 ±18.28) umol/L daily in treatment group, which was obviously higher than that in control group [(39.85 ±19.96)umol/L].The time of treatment in treatment group [(6.45±2.5)d] was obviously shorter than that in control group [(8.28±4.8)d].
Conclusion: With bifidobiogen and qingganlidan oral liquid treating neonatal hyperbilirubinemia, serum bilirubin level could be lowered rapidly and treatment time could be shortened obviously.](./0158_files/image001.gif)